Navigation Links
Alternative Option for Type2 Diabetes Treatment

A class of medications known as incretin-based therapy, which act via certain pathways that affect glucose metabolism may provide modest effectiveness and favorable weight change outcomes for the treatment of type 2 diabetes and may represent an alternative to other hypoglycemic therapies.

Current therapies for type 2 diabetes are often limited by adverse effects such as weight gain or hypoglycemia (low blood sugar). A more recent class of treatment to address these issues is incretin therapy, which involves glucose-stimulated insulin secretion by intestinally derived peptides, which are released in the presence of glucose or nutrients in the gut, according to background information in the article.

In October 2006 the Food and Drug Administration approved the first oral incretin enhancer, sitagliptin, a selective DPP4 inhibitor (a class of oral hypoglycemics), for use as monotherapy or in combination with other medications. The effectiveness of this class of medications in managing type 2 diabetes is not well understood.

Renee E. Amori, M.D., of Tufts-New England Medical Center, Boston, and colleagues conducted a meta-analysis of 29 studies to assess the effectiveness and safety of incretin-based therapy (GLP-1 analogues and DPP4 inhibitors) in nonpregnant adults with type 2 diabetes.

Our analysis of randomized controlled trials showed that incretin-based therapy with GLP-1 analogues or DPP4 inhibitors in adults with type 2 diabetes is moderately effective in improving glycemia, with greater reductions in postprandial [after a meal] glycemia and favorable (GLP-1 analogues) or neutral (DPP4 inhibitors) effects on weight.

Glucagon [a hormone secreted by the pancreas]-like peptide 1 analogues were associated with gastrointestinal adverse effects, while DPP4 inhibitors had a slightly increased risk of infection (nasopharyngitis [inflammation of the nasal passages] and urinary tract infection) and heada che, the authors write.

Incretin therapy offers an alternative option to currently available hypoglycemic agents for nonpregnant adults with type 2 diabetes with modest efficacy and a favorable weight change profile, they write. Individuals with mild diabetes, suggesting an adequate pancreatic beta cell reserve, who are at risk of hypoglycemic sequelae and in need of weight loss may benefit from this new class.

However, these new classes of hypoglycemic agents will need continued evaluation both in long-term efficacy and safety controlled trials and in clinical practice to assess their effectiveness and safety profile to determine their role among the many available and well-established therapies for type 2 diabetes.


'"/>




Related medicine news :

1. Prince Charles lends support to Alternative Medicine
2. Alternative medicine more popular among HIV positive patients
3. Complementary and Alternative medicine
4. Alternative therapies popular with Parkinsons patients
5. Alternative to blood Transfusions
6. Alternative Therapy in HIV Patients
7. An Alternative to Warfarin
8. Another Alternative For Diabetics On Insulin
9. The Use Of Alternative Medicine On The Rise
10. Heart Patients Use Alternative Medicine
11. New Blood Thinner Pill - First Potential Alternative to Warfarin in 50 years
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/23/2017)... Florida (PRWEB) , ... January 23, 2017 , ... ... of the highly acclaimed series, Innovations with Ed Begley, Jr., scheduled to broadcast ... the technology behind SmartCap, which was founded in 2008 to address the limitations ...
(Date:1/23/2017)... ... January 23, 2017 , ... Wooden and plastic balance boards have been around since at ... Kumo Board is the first and only balance board to use a patent-pending ... and rigid at the same time as well as skill-level adjustable for all ages and ...
(Date:1/23/2017)... , ... January 23, 2017 , ... Sharon Kleyne, America’s ... air to educate listeners about the benefits of making new water infrastructure a number ... said, “it’s appropriate that we expect water infrastructure to become a top priority of ...
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... for Assisted Living (IHCA/INCAL), will serve as a healthcare industry expert at the ... The panel discussion, moderated by Inside Indiana Business host Gerry Dick, will feature ...
(Date:1/23/2017)... ... January 23, 2017 , ... Moisture measurement ... the right method is paramount to success. Selecting an inappropriate measurement method can ... multiple persons use the same equipment. Rare or expensive substances are wasted and ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... 23, 2017  Delcath Systems, Inc. (NASDAQ: ... treatment of primary and metastatic liver cancers, today announced ... President and Chief Executive Officer of Delcath will be ... Markets, Thirteenth Annual Investor Conference at the Boca Raton ... , on Tuesday, January 31, 2017 at 10:30 ...
(Date:1/23/2017)... 2017 Varias proteínas clave ... y el riesgo de diálisis están ... pabetalone    Resverlogix Corp. ("Resverlogix" o "la ... un ensayo en fase 1 con sede en Nueva ... severa. Los datos demostraron unos resultados importantes en la ...
(Date:1/23/2017)... The global  anxiety disorders and depression treatment market  is expected to ... depression worldwide is anticipated to drive the market growth in the coming years. ... antidepressants in the recent years. Continue Reading ... ... ...
Breaking Medicine Technology: